Search

Your search keyword '"Federici, A. B."' showing total 732 results
Start Over Author "Federici, A. B."
732 results on '"Federici, A. B."'

1. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

Author

Pagliari, Maria Teresa, Budde, Ulrich, Baronciani, Luciano, Eshghi, Peyman, Ahmadinejad, Minoo, Badiee, Zahra, Baghaipour, Mohammad-Reza, Benítez Hidalgo, Olga, Biguzzi, Eugenia, Bodó, Imre, Castaman, Giancarlo, Goudemand, Jenny, Karimi, Mehran, Keikhaei, Bijan, Lassila, Riitta, Leebeek, Frank W.G., Lopez Fernandez, Maria Fernanda, Marino, Renato, Oldenburg, Johannes, Peake, Ian, Santoro, Cristina, Schneppenheim, Reinhard, Tiede, Andreas, Toogeh, Gholamreza, Tosetto, Alberto, Trossaert, Marc, Yadegari, Hamideh, Zetterberg, Eva M.K., Mannucci, Pier Mannuccio, Federici, Augusto B., Eikenboom, Jeroen, and Peyvandi, Flora

Published
2023
Full Text
View/download PDF

2. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study

Author

Pagliari, Maria Teresa, Rosendaal, Frits R., Ahmadinejad, Minoo, Badiee, Zahra, Baghaipour, Mohammad‐Reza, Baronciani, Luciano, Benítez Hidalgo, Olga, Bodó, Imre, Budde, Ulrich, Castaman, Giancarlo, Eshghi, Peyman, Goudemand, Jenny, Karimi, Mehran, Keikhaei, Bijan, Lassila, Riitta, Leebeek, Frank W.G., Lopez Fernandez, Maria Fernanda, Mannucci, Pier Mannuccio, Marino, Renato, Oldenburg, Johannes, Peake, Ian, Santoro, Cristina, Schneppenheim, Reinhard, Tiede, Andreas, Toogeh, Gholamreza, Tosetto, Alberto, Trossaert, Marc, Yadegari, Hamideh, Zetterberg, Eva M.K., Peyvandi, Flora, Federici, Augusto B., and Eikenboom, Jeroen

Published
2022
Full Text
View/download PDF

3. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

Author

Baronciani, Luciano, Peake, Ian, Schneppenheim, Reinhard, Goodeve, Anne, Ahmadinejad, Minoo, Badiee, Zahra, Baghaipour, Mohammad-Reza, Benitez, Olga, Bodó, Imre, Budde, Ulrich, Cairo, Andrea, Castaman, Giancarlo, Eshghi, Peyman, Goudemand, Jenny, Hassenpflug, Wolf, Hoorfar, Hamid, Karimi, Mehran, Keikhaei, Bijan, Lassila, Riitta, Leebeek, Frank W.G., Lopez Fernandez, Maria Fernanda, Mannucci, Pier Mannuccio, Marino, Renato, Nikšić, Nikolas, Oyen, Florian, Santoro, Cristina, Tiede, Andreas, Toogeh, Gholamreza, Tosetto, Alberto, Trossaert, Marc, Zetterberg, Eva M.K., Eikenboom, Jeroen, Federici, Augusto B., and Peyvandi, Flora

Published
2021
Full Text
View/download PDF

4. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study

Author

Tosetto, Alberto, Badiee, Zahra, Baghaipour, Mohammad‐Reza, Baronciani, Luciano, Battle, Javier, Berntorp, Erik, Bodó, Imre, Budde, Ulrich, Castaman, Giancarlo, Eikenboom, Jeroen C.J., Eshghi, Peyman, Ettorre, Cosimo, Goodeve, Anne, Goudemand, Jenny, Hay, Charles Richard Morris, Hoorfar, Hamid, Karimi, Mehran, Keikhaei, Bijan, Lassila, Riitta, Leebeek, Frank W.G., Lopez Fernandez, Maria Fernanda, Mannucci, Pier Mannuccio, Mazzucconi, Maria Gabriella, Morfini, Massimo, Oldenburg, Johannes, Peake, Ian, Parra Lòpez, Rafael, Peyvandi, Flora, Schneppenheim, Reinhard, Tiede, Andreas, Toogeh, Gholamreza, Trossaert, Marc, Zekavat, Omidreza, Zetterberg, Eva M.K., and Federici, Augusto B.

Published
2020
Full Text
View/download PDF

5. Von Willebrand disease: Gaining a global perspective

Author

O'Sullivan, Jamie M., primary, Tootoonchian, Ellia, additional, Ziemele, Baiba, additional, Makris, Michael, additional, Federici, Augusto B., additional, Khayat Djambas, Claudia, additional, El Ekiaby, Magdy, additional, Rotellini, Dawn, additional, Sidonio, Robert F., additional, Iorio, Alfonso, additional, Coffin, Donna, additional, Pierce, Glenn F., additional, Stonebraker, Jeffrey, additional, James, Paula D., additional, and Lavin, Michelle, additional

Published
2023
Full Text
View/download PDF

7. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

Author

Merli, M, Ferrarini, I, Merli, F, Busca, A, Mina, R, Falini, B, Bruna, R, Cairoli, R, Marchetti, M, Romano, A, Cavo, M, Arcaini, L, Trentin, L, Cattaneo, C, Derenzini, E, Fracchiolla, N, Marchesi, F, Scattolin, A, Billio, A, Bocchia, M, Massaia, M, Gambacorti-Passerini, C, Mauro, F, Gentile, M, Mohamed, S, Della Porta, M, Coviello, E, Cilloni, D, Visani, G, Federici, A, Tisi, M, Cudillo, L, Galimberti, S, Gherlinzoni, F, Pagano, L, Guidetti, A, Bertu, L, Corradini, P, Passamonti, F, Visco, C, Merli M., Ferrarini I., Merli F., Busca A., Mina R., Falini B., Bruna R., Cairoli R., Marchetti M., Romano A., Cavo M., Arcaini L., Trentin L., Cattaneo C., Derenzini E., Fracchiolla N. S., Marchesi F., Scattolin A., Billio A., Bocchia M., Massaia M., Gambacorti-Passerini C., Mauro F. R., Gentile M., Mohamed S., Della Porta M. G., Coviello E., Cilloni D., Visani G., Federici A. B., Tisi M. C., Cudillo L., Galimberti S., Gherlinzoni F., Pagano L., Guidetti A., Bertu L., Corradini P., Passamonti F., Visco C., Merli, M, Ferrarini, I, Merli, F, Busca, A, Mina, R, Falini, B, Bruna, R, Cairoli, R, Marchetti, M, Romano, A, Cavo, M, Arcaini, L, Trentin, L, Cattaneo, C, Derenzini, E, Fracchiolla, N, Marchesi, F, Scattolin, A, Billio, A, Bocchia, M, Massaia, M, Gambacorti-Passerini, C, Mauro, F, Gentile, M, Mohamed, S, Della Porta, M, Coviello, E, Cilloni, D, Visani, G, Federici, A, Tisi, M, Cudillo, L, Galimberti, S, Gherlinzoni, F, Pagano, L, Guidetti, A, Bertu, L, Corradini, P, Passamonti, F, Visco, C, Merli M., Ferrarini I., Merli F., Busca A., Mina R., Falini B., Bruna R., Cairoli R., Marchetti M., Romano A., Cavo M., Arcaini L., Trentin L., Cattaneo C., Derenzini E., Fracchiolla N. S., Marchesi F., Scattolin A., Billio A., Bocchia M., Massaia M., Gambacorti-Passerini C., Mauro F. R., Gentile M., Mohamed S., Della Porta M. G., Coviello E., Cilloni D., Visani G., Federici A. B., Tisi M. C., Cudillo L., Galimberti S., Gherlinzoni F., Pagano L., Guidetti A., Bertu L., Corradini P., Passamonti F., and Visco C.

Abstract

COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38–94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow-up of 42 days (IQR 24–96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020–22 June 2020) and second wave (23 June 2020–1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03–3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23–4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04–2.84, p = 0.04) and COVID-19 severity (severe: HR 5.66, 95% CI 2.62–12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93–36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID-related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters.

Published
2023

9. Sixth Åland Island Conference on von Willebrand disease

Author

Berntorp, Erik, primary, Trakymienė, Sonata S., additional, Federici, Augusto B., additional, Holstein, Katharina, additional, Corrales‐Medina, Fernando F., additional, Pierce, Glenn F., additional, Srivastava, Alok, additional, Prondzinski, Mario von Depka, additional, Johnsen, Jill M., additional, Zupan, Irena P., additional, Halimeh, Susan, additional, Nummi, Vuokko, additional, and Roberts, Jonathan C., additional

Published
2022
Full Text
View/download PDF

12. Use of the von Willebrand factor concentrate with low factor VIII content to manage patients with inherited von Willebrand disease requiring surgical or secondary long‐term prophylaxis: an expert opinion paper from an Italian panel

Author

Castaman, Giancarlo, primary, Borchiellini, Alessandra, additional, Coppola, Antonio, additional, Cultrera, Dorina, additional, Marino, Renato, additional, Federici, Augusto B., additional, Giuffrida, Anna Chiara, additional, Marchesini, Emanuela, additional, Molinari, Angelo Claudio, additional, Siboni, Simona Maria, additional, and Zanon, Ezio, additional

Published
2022
Full Text
View/download PDF

14. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel

Author

James, Andra H., Kouides, Peter A., Abdul-Kadir, Rezan, Dietrich, Jennifer E., Edlund, Mans, Federici, Augusto B., Halimeh, Susan, Kamphuisen, Pieter Willem, Lee, Christine A., Martínez-Perez, Oscar, McLintock, Claire, Peyvandi, Flora, Philipp, Claire, Wilkinson, Jeffrey, and Winikoff, Rochelle

Published
2011
Full Text
View/download PDF

18. Efficacy and safety evaluation of Fanhdi ® , a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study

Author

Jimenez‐Yuste, Victor, primary, Núñez, Laura, additional, Alvarez‐Roman, Maria Teresa, additional, Martin‐Salces, Monica, additional, Haya, Saturnino, additional, Federici, Augusto B., additional, Grifols, Carlota, additional, Mairal, Esther, additional, Torres, Mireia, additional, and Páez, Antonio, additional

Published
2021
Full Text
View/download PDF

27. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)

Author

Haberichter, Sandra L., Castaman, Giancarlo, Budde, Ulrich, Peake, Ian, Goodeve, Anne, Rodeghiero, Francesco, Federici, Augusto B., Batlle, Javier, Meyer, Dominique, Mazurier, Claudine, Goudemand, Jenny, Eikenboom, Jeroen, Schneppenheim, Reinhard, Ingerslev, Jorgen, Vorlova, Zdena, Habart, David, Holmberg, Lars, Lethagen, Stefan, Pasi, John, Hill, Frank G.H., and Montgomery, Robert R.

Published
2008
Full Text
View/download PDF

28. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD

Author

Castaman, Giancarlo, Lethagen, Stefan, Federici, Augusto B., Tosetto, Alberto, Goodeve, Anne, Budde, Ulrich, Batlle, Javier, Meyer, Dominique, Mazurier, Claudine, Fressinaud, Edith, Goudemand, Jenny, Eikenboom, Jeroen, Schneppenheim, Reinhard, Ingerslev, Jorgen, Vorlova, Zdena, Habart, David, Holmberg, Lars, Pasi, John, Hill, Frank, Peake, Ian, and Rodeghiero, Francesco

Published
2008
Full Text
View/download PDF

33. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Author

Passamonti, F, Cattaneo, C, Arcaini, L, Bruna, R, Cavo, M, Merli, F, Angelucci, E, Krampera, M, Cairoli, R, Della Porta, M, Fracchiolla, N, Ladetto, M, Gambacorti Passerini, C, Salvini, M, Marchetti, M, Lemoli, R, Molteni, A, Busca, A, Cuneo, A, Romano, A, Giuliani, N, Galimberti, S, Corso, A, Morotti, A, Falini, B, Billio, A, Gherlinzoni, F, Visani, G, Tisi, M, Tafuri, A, Tosi, P, Lanza, F, Massaia, M, Turrini, M, Ferrara, F, Gurrieri, C, Vallisa, D, Martelli, M, Derenzini, E, Guarini, A, Conconi, A, Cuccaro, A, Cudillo, L, Russo, D, Ciambelli, F, Scattolin, A, Luppi, M, Selleri, C, Ortu La Barbera, E, Ferrandina, C, Di Renzo, N, Olivieri, A, Bocchia, M, Gentile, M, Marchesi, F, Musto, P, Federici, A, Candoni, A, Venditti, A, Fava, C, Pinto, A, Galieni, P, Rigacci, L, Armiento, D, Pane, F, Oberti, M, Zappasodi, P, Visco, C, Franchi, M, Grossi, P, Bertu, L, Corrao, G, Pagano, L, Corradini, P, Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., Angelucci E., Krampera M., Cairoli R., Della Porta M. G., Fracchiolla N., Ladetto M., Gambacorti Passerini C., Salvini M., Marchetti M., Lemoli R., Molteni A., Busca A., Cuneo A., Romano A., Giuliani N., Galimberti S., Corso A., Morotti A., Falini B., Billio A., Gherlinzoni F., Visani G., Tisi M. C., Tafuri A., Tosi P., Lanza F., Massaia M., Turrini M., Ferrara F., Gurrieri C., Vallisa D., Martelli M., Derenzini E., Guarini A., Conconi A., Cuccaro A., Cudillo L., Russo D., Ciambelli F., Scattolin A. M., Luppi M., Selleri C., Ortu La Barbera E., Ferrandina C., Di Renzo N., Olivieri A., Bocchia M., Gentile M., Marchesi F., Musto P., Federici A. B., Candoni A., Venditti A., Fava C., Pinto A., Galieni P., Rigacci L., Armiento D., Pane F., Oberti M., Zappasodi P., Visco C., Franchi M., Grossi P. A., Bertu L., Corrao G., Pagano L., Corradini P., Passamonti, F, Cattaneo, C, Arcaini, L, Bruna, R, Cavo, M, Merli, F, Angelucci, E, Krampera, M, Cairoli, R, Della Porta, M, Fracchiolla, N, Ladetto, M, Gambacorti Passerini, C, Salvini, M, Marchetti, M, Lemoli, R, Molteni, A, Busca, A, Cuneo, A, Romano, A, Giuliani, N, Galimberti, S, Corso, A, Morotti, A, Falini, B, Billio, A, Gherlinzoni, F, Visani, G, Tisi, M, Tafuri, A, Tosi, P, Lanza, F, Massaia, M, Turrini, M, Ferrara, F, Gurrieri, C, Vallisa, D, Martelli, M, Derenzini, E, Guarini, A, Conconi, A, Cuccaro, A, Cudillo, L, Russo, D, Ciambelli, F, Scattolin, A, Luppi, M, Selleri, C, Ortu La Barbera, E, Ferrandina, C, Di Renzo, N, Olivieri, A, Bocchia, M, Gentile, M, Marchesi, F, Musto, P, Federici, A, Candoni, A, Venditti, A, Fava, C, Pinto, A, Galieni, P, Rigacci, L, Armiento, D, Pane, F, Oberti, M, Zappasodi, P, Visco, C, Franchi, M, Grossi, P, Bertu, L, Corrao, G, Pagano, L, Corradini, P, Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., Angelucci E., Krampera M., Cairoli R., Della Porta M. G., Fracchiolla N., Ladetto M., Gambacorti Passerini C., Salvini M., Marchetti M., Lemoli R., Molteni A., Busca A., Cuneo A., Romano A., Giuliani N., Galimberti S., Corso A., Morotti A., Falini B., Billio A., Gherlinzoni F., Visani G., Tisi M. C., Tafuri A., Tosi P., Lanza F., Massaia M., Turrini M., Ferrara F., Gurrieri C., Vallisa D., Martelli M., Derenzini E., Guarini A., Conconi A., Cuccaro A., Cudillo L., Russo D., Ciambelli F., Scattolin A. M., Luppi M., Selleri C., Ortu La Barbera E., Ferrandina C., Di Renzo N., Olivieri A., Bocchia M., Gentile M., Marchesi F., Musto P., Federici A. B., Candoni A., Venditti A., Fava C., Pinto A., Galieni P., Rigacci L., Armiento D., Pane F., Oberti M., Zappasodi P., Visco C., Franchi M., Grossi P. A., Bertu L., Corrao G., Pagano L., and Corradini P.

Abstract

Background: Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who required hospitalisation for COVID-19. Methods: This multicentre, retrospective, cohort study included adult patients (aged ≥18 years) with diagnosis of a WHO-defined haematological malignancy admitted to 66 Italian hospitals between Feb 25 and May 18, 2020, with laboratory-confirmed and symptomatic COVID-19. Data cutoff for this analysis was June 22, 2020. The primary outcome was mortality and evaluation of potential predictive parameters of mortality. We calculated standardised mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality rates of the Italian population with COVID-19 and an Italian cohort of 31 993 patients with haematological malignancies without COVID-19 (data up to March 1, 2019). Multivariable Cox proportional hazards model was used to identify factors associated with overall survival. This study is registered with ClinicalTrials.gov, NCT04352556, and the prospective part of the study is ongoing. Findings: We enrolled 536 patients with a median follow-up of 20 days (IQR 10–34) at data cutoff, 85 (16%) of whom were managed as outpatients. 440 (98%) of 451 hospitalised patients completed their hospital course (were either discharged alive or died). 198 (37%) of 536 patients died. When compared with the general Italian population with COVID-19, the standardised mortality ratio was 2·04 (95% CI 1·77–2·34) in our whole study cohort and 3·72 (2·86–4·64) in individuals younger than 70 years. When compared with the non-COVID-19 cohort with haematological malignancies, the standardised mortality ratio was 41·3 (38·1–44·9). Older age (hazard ratio 1·03, 95% CI 1·01–1·05); progressive disease status (2·10, 1·41–3·12); diagnosis of

Published
2020

45. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease

Author

Castaman, G., Coppola, A., Zanon, E., Boeri, E., Musso, M., Siragusa, S., Federici, A. B., Mancuso, G., Barillari, G., Biasoli, C., Feola, G., Franchini, M., Moratelli, S., Gamba, G., Schinco, P., Valdrè, L., Dragani, A., Mazzucconi, G., Tagliaferri, A., and Morfini, M.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results